Anales de la RANM

123 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 ASPIRINA EN PREVENCIÓN PRIMARIA CARDIOVASCULAR Berrazueta Fernández JR An RANM. 2023;140(02):114 - 124 BIBLIOGRAFÍA 1. Tsoucalasi G, Karamanoui M, Androutsosi G. Traveling through time with aspirin, a healing companion. Eur J Inflammation. 2011; 9: 13- 16. 2. Vane JR. Inhibition of prostaglandin synthe- sis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971; 231(25): 230-235. 3. Ferreira SH, Moncada S, Vane JR. Indometha- cin and aspirin abolish prostaglandin release from the splen. Nat New Biol. 1971; 231(25): 237-239. 4. Ferreira SH, Moncada S, Vane JR. Prostaglnd- ins and the mechanism of analgesia produced by aspirin-like drugs. Br J Pharmacol. 1973; 49: 86-97. 5. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA. 1975; 72(8): 2994-2998. 6. Needleman P, Moncada S, Bunting S, Vane JR, Hamberg M, Samuelson B. Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglan- din endoperoxides. Nature. 1976; 261: 558- 560. 7. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unsta- ble substance that inhibits platelet aggrega- tion. Nature. 1976; 263(5579): 663-665. doi: 10.1038/263663a0. 8. Whittaker N, Bunting S, Salmon J et al. The chemical structure of prostaglandin X (pros- tacyclin). Prostaglandins. 1976; 126: 915-928. doi: 10.1016/0090-6980(76)90126-x. 9. Burch JW, Stanford N, Majerus PhW. Inhi- bition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest. 1978; 61: 314- 319. 10. Baenziger NL, Dillender MJ, Majerus PhW. Cultured human skin fibroblasts and arte- rial cells produce a labile platelet-inhibitor y prostaglandin. Biochem Biophys Res Com- mun. 1977; 78(1): 294-301. doi: 10.1016/0006- 291x(77)91253-0. 11. Pedersen AK, Garret A, FitzGerald GA. Dose- related kinetics of aspirin- presystemic ace- tylation of platelet cyclooxygenase. N Engl J Med. 1984; 311: 1206-1211. doi: 10.1056/ NEJM198411083111902. 12. O’Grady J, Moncada S. Aspirin: a para- doxical effect on bleeding time. Lancet. 1978; 312(8093): 780. doi: 10.1016/s0140- 6736(78)92661-2. 13. Moncada S. Aventuras en farmacología: Veinte años de casualidad y diseño: Discurso de in- greso como Académico de Honor de la Real Academia Nacional de Medicina. Laudatio por Pedro Sánchez García. An R Acad Nac Med. 1994; 111: 853-910. 14. Miner J, Hoffhines A. The discovery of aspirin’s antithrombotic effects. Tex Heart Inst J. 2007; 34(2): 179-186. 15. Second International Study of Infarct Survival Collaborative Group. Randomised trial of in- travenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acu- te myocardial infarction: ISIS-2. Lancet. 1988; 2(8607): 349-360. 16. Peto R, Gray R, Collins R et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed). 1988; 296: 313-316. 17. Steering Committee of the Physicians’ Health Study Research Group. Final report on the as- pirin component of the ongoing Physicians’ Health Study. N Engl J Med. 1989; 321(3): 129- 135. 18. Steering Committee of the Physicians’ Health Study Research Group. Final report on the as- pirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989; 321(3): 129- 135. 19. The Medical Research Council’s General Prac- tice Research Framework. Thrombosis preven- tion trial: Randomised trial of low-intensity oral anticoagulation with warfarin and low- dose aspirin in the primary prevention of is- chaemic heart disease in men at increased risk. Lancet. 1998; 351(9098): 233-241. 20. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hyper- tension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998; 351(9118): 1755-1762. 21. De Gaetano G; Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet. 2001; 357(9250): 89-95. 22. Ridker PM, Cook NR, Lee IM. A randomized trial of low-dose aspirin in the primary pre- vention of cardiovascular disease in women. N Engl J Med. 2005; 352(13) :1293-1304. 23. Belch J, MacCuish A, Campbell I et al; Pre- vention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh. The prevention of progression of arterial di- sease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008; 337: a1840. 24. Ogawa H, Makayama M, Morimoto T et al; Ja- panese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Inves- tigators. Low-dose aspirin for primary preven- tion of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008; 300(18): 2134-2141. 25. Fowkes FG, Price JF, Stewart MC et al; Aspi- rin for Asymptomatic Atherosclerosis Tria- lists. Aspirin for prevention of cardiovascu- lar events in a general population screened for a low ankle brachial index: a randomi- zed controlled trial. JAMA. 2010; 303(9): 841-848.